FDA Says Dibenzyline Wasn't Pulled for Safety or Effectiveness
Published Date: 11/13/2026
Notice
Summary
The FDA has decided that Dibenzyline (Phenoxybenzamine Hydrochloride) 10 mg capsules and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic versions can keep getting approved as long as they meet the rules. Patients and drug makers can breathe easy knowing these meds stay on the list and available.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Generic Approvals Can Continue
The FDA says it will continue to allow abbreviated new drug applications (ANDAs) that refer to the listed drugs to be approved if they meet legal and regulatory requirements. This specifically includes drugs listed in the notice such as DIBENZYLINE (Phenoxybenzamine Hydrochloride) 10 mg (NDA 008708).
Existing Generic Approvals Unchanged
Approved ANDAs that refer to the listed drug products are unaffected by the products' discontinued marketing. For example, ANDAs that reference DIBENZYLINE (Phenoxybenzamine Hydrochloride) 10 mg (NDA 008708) remain approved.
Products Listed as Discontinued (Not Safety Issues)
The FDA will continue to list the named products in the Orange Book's "Discontinued Drug Product List," which identifies drugs discontinued from marketing for reasons other than safety or effectiveness. The notice names multiple products, including DIBENZYLINE (NDA 008708) and others on the table in the document.
Possible Labeling Revisions for Applicants
The FDA says that if it determines labeling for these drug products should be revised to meet current standards, the Agency will advise ANDA applicants to submit such labeling. This applies to the drugs named in the notice, for example DIBENZYLINE (NDA 008708).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-23139, Environmental Impact Statements; Notice of Availability
The EPA just announced new Environmental Impact Statements (EIS) for projects like flood control in Missouri, a solar project in Nevada, and pipeline safety updates. These reports affect communities, businesses, and the environment, with public review deadlines coming up by mid-December and early January. If you care about clean air, safety, or energy, now’s the time to check out these plans and share your thoughts!
Next: 2026-23142, South Atlantic Fishery Management Council; Public Meeting
The South Atlantic Fishery Management Council is holding a big meeting from December 7-11, 2026, to talk about managing fish like dolphin, wahoo, golden crab, and snapper grouper. Fishermen, scientists, and the public can join in person or online to share ideas and help shape fishing rules. This meeting could lead to new fishing plans that affect how much fish can be caught and when, helping protect ocean life and local fishing jobs.